In a previous study, a poorer efficacy of BRAF inhibitors was observed in metastatic melanoma patients with germline MC1R variants (R), possibly related to altered p38 MAP kinase phosphorylation (Guida et al. 2016). Here, MC1R is linked to metastatic melanoma.